|
Bladder Neoplasm
|
0.600 |
GeneticVariation
|
disease |
UNIPROT |
|
|
|
|
Bladder Neoplasm
|
0.600 |
PosttranslationalModification
|
disease |
BEFREE |
Our data show a significant correlation (P = 0.00001, two-sided) between the absence of p16/CDKN2 expression and methylation of its 5' CpG island in bladder tumors, cell lines, and normal colon mucosa.
|
7553622 |
1995 |
|
Bladder Neoplasm
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Homozygous deletion (both alleles lost) of the p16 and the p15 genes was observed in 11 and nine bladder tumors, respectively.
|
7563186 |
1995 |
|
Bladder Neoplasm
|
0.600 |
Biomarker
|
disease |
BEFREE |
No sequence mutations were detected in exons 1 or 2 of either p15 or p16 in any of the bladder tumors.
|
7576106 |
1995 |
|
Bladder Neoplasm
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
The p15 and p16 genes are known to be juxtaposed on chromosome 9p21 at the locus of a putative tumour-suppressor gene involved in the initiation of bladder cancer.
|
7577470 |
1995 |
|
Bladder Neoplasm
|
0.600 |
Biomarker
|
disease |
BEFREE |
At the 9p arm is located the p16 (MTS1) TSG and probably others with an effect on various human tumours such as acute lymphoblastic leukaemia, bladder cancer, gliomas, malignant mesotheliomas, melanomas and non-small cell lung carcinomas.
|
7585472 |
1995 |
|
Bladder Neoplasm
|
0.600 |
Biomarker
|
disease |
BEFREE |
We conclude that p16 represents the major target for deletion at 9p21 in bladder cancer.
|
8541841 |
1995 |
|
Bladder Neoplasm
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Infrequent somatic mutations of the p16 and p15 genes in human bladder cancer: p16 mutations occur only in low-grade and superficial bladder cancers.
|
8747595 |
1995 |
|
Bladder Neoplasm
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Three conclusions can be drawn from our findings: (i) p16(INK4) alterations are more frequent in cell lines than in primary tumors; (ii) in primary bladder tumors (bilharziasis-associated or not), p16(INK4) deletions are much more frequent than p16(INK4) mutations; (iii) p16(INK4) alterations are more frequent in bilharziasis-associated bladder tumors than in other bladder tumors.
|
8900425 |
1996 |
|
Bladder Neoplasm
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Therefore, we applied gene-specific probes for CDKN2 and the interferon alpha gene (IFNA), also located at 9p21, to characterize further the genomic deletions at this locus in bladder cancer.
|
9171998 |
1997 |
|
Bladder Neoplasm
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Deletion analysis at the DEL-27, APC and MTS1 loci in bladder cancer: LOH at the DEL-27 locus on 5p13-12 is a prognostic marker of tumor progression.
|
9221807 |
1997 |
|
Bladder Neoplasm
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
We measured the CDKN2A/p16 tumor suppressor gene locus in bladder irrigation specimens and correlated the measurement with the clinical status of patients with bladder cancer.
|
9334586 |
1997 |
|
Bladder Neoplasm
|
0.600 |
Biomarker
|
disease |
BEFREE |
Using a novel approach, we tested these hypotheses in the present study by examining p16 and pRb status in primary culture (P0) and after passage in vitro of transitional cell carcinoma (TCC) biopsies that represented both superficial bladder tumors and invasive bladder cancers.
|
9436977 |
1998 |
|
Bladder Neoplasm
|
0.600 |
Biomarker
|
disease |
BEFREE |
Detailed methylation analysis using genomic bisulfite sequencing was performed on a series of subclones of a bladder cancer cell line in which a hypermethylated p16 gene had been reactivated by transient treatment with 5-aza-2'-deoxycytidine.
|
9515812 |
1998 |
|
Bladder Neoplasm
|
0.600 |
Biomarker
|
disease |
BEFREE |
A comparison between microsatellite and quantitative PCR analyses to detect frequent p16 copy number changes in primary bladder tumors.
|
9516934 |
1998 |
|
Bladder Neoplasm
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Presence and location of TP53 mutation determines pattern of CDKN2A/ARF pathway inactivation in bladder cancer.
|
9850064 |
1998 |
|
Bladder Neoplasm
|
0.600 |
Biomarker
|
disease |
BEFREE |
These results strongly support the hypothesis that the RB nuclear overexpression recently associated with poor prognosis in bladder cancer is also associated with loss of p16 function and implies that loss of p16 function could be equally deleterious as RB loss in bladder and likely other cancers.
|
10022125 |
1999 |
|
Bladder Neoplasm
|
0.600 |
PosttranslationalModification
|
disease |
BEFREE |
In conclusion, deletions and methylation of the INK4A gene occur frequently in superficial bladder tumors.
|
10393843 |
1999 |
|
Bladder Neoplasm
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
These observations as well as the observation that bladder cancer is associated with deletions of CDKN2, a gene important in normal senescence, led us to examine normal urothelial cell response to H2O2.
|
10938379 |
2000 |
|
Bladder Neoplasm
|
0.600 |
PosttranslationalModification
|
disease |
BEFREE |
To see whether normal mucosa had already acquired genetic or epigenetic changes, we examined loss of heterozygosity (LOH) at 10 microsatellite loci and methylation of the p16(INK4) CpG island in multiple tumors and pathologically normal mucosa in six patients with bladder cancer.
|
10945601 |
2000 |
|
Bladder Neoplasm
|
0.600 |
Biomarker
|
disease |
BEFREE |
Alteration of the p16 and p15 genes appears to be an early event in bladder cancer which occurs more frequently in SABC and SCC, and may play an important role in the development of schistosomal bladder cancer.
|
10958872 |
2000 |
|
Bladder Neoplasm
|
0.600 |
Biomarker
|
disease |
BEFREE |
High frequency of p16 alteration and high local recurrence rate of bladder cancer make this cancer an ideal target for p16 gene therapy.
|
11205911 |
2001 |
|
Bladder Neoplasm
|
0.600 |
Biomarker
|
disease |
BEFREE |
To better define cytogenetic mechanisms of CDKN2 loss at 9p21 and of DBCCR1 loss at 9q33 in bladder cancer, and to determine correlation with p53 and pRb.
|
11410506 |
2001 |
|
Bladder Neoplasm
|
0.600 |
PosttranslationalModification
|
disease |
LHGDN |
In 22 paired voided urine samples of bladder cancer, methylation of DAPK, RARbeta, E-cadherin, and p16 could be detected in 45.5%, 68.2%, 59.1%, and 13.6% of the cases, respectively.
|
11839665 |
2002 |
|
Bladder Neoplasm
|
0.600 |
PosttranslationalModification
|
disease |
LHGDN |
We analyzed loss of heterozygosity in six microsatellite markers (D17S695, D17S654, D13S310, TH2, D9S747, and D9S161), p53 and K-ras mutations, and the promoter status of p14ARF and p16INK4a in the mononuclear normal blood cells, tumor, and plasma DNA of 27 bladder cancer patients.
|
11948103 |
2002 |